Graphium biosciences inc
WebOct 26, 2024 · Type: Grant Filed: September 22, 2016 Date of Patent: December 28, 2024 Assignee: Graphium Biosciences, Inc. Inventors: Brandon J. Zipp, Janee M. Hardman, … Web--MALACHITE INNOVATIONS, INC. announces that its wholly-owned drug development subsidiary, Graphium Biosciences, Inc., has been granted two patents by the U.S. …
Graphium biosciences inc
Did you know?
WebSince we were founded in 1989, we've focused on providing innovative solutions for education and business. Get in touch. 45190 Prologis Plaza, Suite 165. Dulles , VA … WebOct 12, 2024 · Graphium Biosciences, our operating subsidiary dedicated to improving the health and wellness of people, seeks to advance our broad portfolio of over 100 novel cannabinoid-glycoside compounds created using our proprietary enzymatic bioprocessing technologies to develop safe and effective novel treatments for chronic and debilitating …
WebDec 28, 2024 · Graphium Biosciences, our operating subsidiary dedicated to improving the health and wellness of people, seeks to advance our broad portfolio of over 100 novel … WebAvidity Biosciences, Inc. San Diego Metropolitan Area 10 minutes ago Be among the first 25 applicants See who Avidity Biosciences, Inc. has hired for this role
WebApr 6, 2024 · 40. Free-Float. 52,6%. More Financials. Company. Malachite Innovations, Inc. is a holding company, which operates through its subsidiaries Graphium Biosciences, Inc. and Daedalus Ecosciences, Inc. The Company focuses on improving the health and wellness of people and the planet. Its segments include Therapeutic Operations and … Web4.4K 52-Wk Range 0.1201 - 0.2986 (04/28/22 - 10/11/22) 33.22% Historical Volatility 149.3% Market Cap 12.5M Shares Outstanding 78.1M EPS (TTM, GAAP) -0.03 P/E Ratio (TTM, GAAP) -- Annual Dividend/Yield No dividend Ex-dividend Date No dividend Dividend Pay Date No dividend Beta 2.6 % Held by Institutions 0.10 Short Interest --
WebMar 31, 2024 · Its Graphium Biosciences, Inc. is focused on advancing its portfolio of over 100 cannabinoid-glycoside compounds created using its enzymatic bioprocessing technologies to develop treatments for chronic and debilitating conditions. Daedalus Ecosciences, Inc. (Daedalus). is focused on the health and wellness through …
WebI n October 2024, the Company reorganized its corporate structure and created the following two wholly-owned operating subsidiaries: (i) Graphium Biosciences, Inc., a Nevada … biomarker of breast cancerWebGraphium Biosciences, Inc. is a cannabinoid-based drug development company tracing its history of technological innovation and drug advancement back to October 2011 through two predecessor ... biomarker research endnoteWebGraphium Biosciences, our operating subsidiary dedicated to improving the health and wellness of people, seeks to advance our broad portfolio of over 100 novel cannabinoid … biomarker for thrombotic activityWebApr 13, 2024 · Malachite Innovations Inc Actions Add to watchlist Add to portfolio Add an alert Price (USD)0.19 Today's Change0.00 / 0.00% Shares traded23.82k 1 Year change-46.48% Beta2.5872 Data delayed at... biomark device manager manualdaily plant inspection sheetWebDec 31, 2024 · Graphium Biosciences, Inc. (“Graphium”) is a cannabinoid-based drug development company tracing its history of technological innovation and drug advancement back to October 2011 through two predecessor entities, Stevia First Corp. and Vitality Biopharma, Inc. In October 2024, Malachite formed Graphium as a wholly-owned … daily planner with times printableWebMar 24, 2024 · Its Graphium Biosciences, Inc. is focused on advancing its portfolio of over 100 cannabinoid-glycoside compounds created using its enzymatic bioprocessing technologies to develop treatments for chronic and debilitating conditions. Daedalus Ecosciences, Inc. (Daedalus). is focused on the health and wellness through … biomarker research if